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Ischemia–reperfusion injuryThe mitochondrial permeability transition (PT) – an abrupt increase permeability of the inner membrane to
solutes – is a causative event in ischemia–reperfusion injury of the heart, and the focus of intense research in
cardioprotection. The PT is due to opening of the PT pore (PTP), a high conductance channel that is critically reg-
ulated by a variety of pathophysiological effectors. Very recent work indicates that the PTP forms from the F-
ATP synthase, which would switch from an energy-conserving to an energy-dissipating device. This review pro-
vides an update on the current debate on how this transition is achieved, and on the PTP as a target for
therapeutic intervention. This article is part of a Special Issue entitled "Mitochondria: from basic mitochondrial
biology to cardiovascular disease".
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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The permeability transition (PT) is an abrupt increase of the inner
mitochondrial membrane (IMM) permeability to solutes, which in
mammalian mitochondria has a cutoff of about 1500 Da. Occurrence of
the PT and its inhibition by adenine nucleotides is known since the
1950s [1,2], and the phenomenon has been investigated in a number of
laboratories (e.g. [3–13]). The term “permeability transition”was intro-
duced in 1979 byHaworth andHunter, who carried out a thorough char-
acterization of its basic features in heart mitochondria, and provided the
important insight –which is today generally accepted – that the PT could
be due to opening of an IMM channel, the PTP [14–17]. This hypothesis
was conﬁrmed by patch-clamp studies on mammalian mitoplasts,
which revealed the presence of a high-conductance (≈1 nS) channel,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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the basic features of the PTP [20,21] including sensitivity to cyclosporin
A (CsA) [22], and represents the electrophysiological equivalent of the
pore [23]. The study of mitochondrial channels has greatly contributed
to our understanding ofmitochondrial physiology, and to the acceptance
of the pore theory of the PT (see [24] for a recent review).
PTP opening is traditionally linked to mitochondrial dysfunction be-
cause its occurrence leads to mitochondrial depolarization, cessation of
ATP synthesis, Ca2+ release, pyridine nucleotide depletion, inhibition of
respiration and, in vitro at least, matrix swelling; in turn, swelling
causes mobilization of cytochrome c, outer mitochondrial membrane
(OMM) rupture and eventually release of proapoptotic proteins such
as cytochrome c itself, endonuclease G and AIF [25,26]. It should be
mentioned that these detrimental effects on energy conservation and
cell viability are only seen for long-lasting openings of the PTP [27],
while short-term openings – which have been documented both in
isolated mitochondria and in situ [27–30] –may be involved in physio-
logical regulation of Ca2+ and reactive oxygen species (ROS) homeosta-
sis [31], and provide mitochondria with a fast mechanism for Ca2+
release [32–35]. The potential role of the PTP in heart injury has been
recognized very early [36,37], well before the role of mitochondria in
apoptosis was discovered [38–40]. PTP desensitization with CsA proved
beneﬁcial in heart ischemia–reperfusion injury, as well as in pre- and
post-conditioning throughmechanisms that await clariﬁcation [41–49].
Matrix Ca2+ is an essential permissive factor for PTP opening, but
the role of mitochondrial “Ca2+ overload” as a causative event in I/R
injury of the heart has recently been challenged. InMCU null mitochon-
dria – where Ca2+ overload does not occur during reperfusion – the
extent of necrosis was the same as that observed in the hearts from
wild type littermates, and the cardioprotective effect of CyPD ablation
was abrogated [50]. These surprising observations raise many issues
that still await an answer, such as the cause of cell death, themechanism
of activation of mitochondrial metabolism and the mechanism of
PTP opening in MCU null mice. Yet these experiments do show that
cardiomyocyte cell death can occur without mitochondrial “Ca2+ over-
load”; and suggest that there is enough Ca2+ in the matrix of MCU null
mitochondria to allow pore PTP opening, possibly a consequence of the
burst of ROS that follows reperfusion [31].
2. Molecular nature of the permeability transition pore: the early
days
The molecular nature of the PTP has been the matter of debate for
the last 30 years. In the early 1990s Snyder and coworkers found that
the peripheral benzodiazepine receptor, an OMM protein today called
TSPO [51], copuriﬁed with the adenine nucleotide translocator (ANT)
and the voltage-dependent anion channel (VDAC) in protocols based
on detergent extraction followed by hydroxylapatite chromatography;
radiolabeled high-afﬁnity ligands of TSPO were recovered in fractions
where TSPO could be detected together with VDAC and ANT [52]. This
ﬁnding was of great interest because nanomolar concentrations of the
same TSPO ligands affected the channel properties of MMC in electro-
physiological experiments, suggesting that all of these proteins could
be involved in formation of the PTP [53].
This suggestionwas strengthened a fewyears later bywork from the
Brdiczka laboratory during the characterization of OMM and IMM “con-
tact sites”, i.e. specialized structures where the two membranes form
close contacts mediated by protein–protein interactions [54]. These
sites would include hexokinase on the cytosolic surface of, and VDAC
within, the OMM, creatine kinase and nucleoside diphosphate kinase
in the intermembrane space, and ANT in the IMM; they were proposed
tomediate channeling of adenine nucleotides to and frommitochondria
[54–56]. The link with the PTP was made when the same laboratory
showed that hexokinase-enriched fractions from lowdetergent extracts
of mitochondria formed channels with the conductance expected of the
PTP, and conferred permeability properties to liposomes that could beinhibited by N-methylVal-4-cyclosporin [57]. It must be stressed that
the preparation contained a very large number of proteins, which
makes assignment of the channel activity to a speciﬁc species quite
problematic. Furthermore – and unlike the case of PTP – currents
were inhibited rather than induced by atractylate, and the active
fractions were not enriched in VDAC and/or ANT [57]. The same prepa-
rationswere shown to also contain proteins of the Bcl-2 family [58], and
this set of observations led to a model where the PTP would be a
multiprotein complex spanning both mitochondrial membranes and
comprising ANT, VDAC, TSPO, cyclophilin (CyP) D as well as hexokinase
and Bcl-2 proteins [59]. This model did not stand the test of genetics, as
a CsA-sensitive PT could be easily detected in the absence of ANT [60],
VDAC [61,62] as well as of TSPO [63]. An alternativemodel is the forma-
tion of the PTP by the Pi carrier following its interactionwith CyP-D and
ANT [64]. However, results obtained by patch-clamp analysis of the
reconstituted Pi carrier do not match the electrophysiological PTP
features [65] and genetic deletion of the Pi carrier does not support
the idea that this protein is essential for PTP formation [66].
Studies on Ppif−/− mice (Ppif is the unique gene encoding CyPD in
themouse) have demonstrated that this protein is an important modu-
lator which sensitizes the PTP to Ca2+ and confers sensitivity to CsA, but
not an essential pore component [67–70]. By following the interactions
of the matrix CyPD with other mitochondrial proteins it has recently
been possible to identify a novel structure for the PTP, which will be
described in the following paragraph.
3. The permeability transition pore forms from F-ATP synthase
Bymonitoring the presence of CyPD in blue native gels of mitochon-
drial proteins Giorgio et al. discovered that CyPD interacts with the F-
ATP synthase, and that it can be crosslinked to the stalk proteins b, d
and OSCP [71]. Binding of CyPD to the F-ATP synthase required Pi, and
caused a decrease of the enzyme's catalytic activity; while it was
counteracted by CsA, which displaced CyPD and increased the catalytic
activity [71]. It was then found that CyPD interacts with the OSCP
subunit of F-ATP synthase [72]. Gel-puriﬁed dimers of F-ATP synthase
incorporated into lipid bilayers displayed currents activated by Ca2+,
Bz-243 and phenylarsine oxide (but not atractylate)with a unit conduc-
tance of about 500 pS, which is identical to that of the bona ﬁde mam-
malian MMC-PTP [72]. The channel-forming property is shared by
puriﬁed F-ATP synthase dimers of yeast mitochondria, which also
displayed Ca2+-dependent currents of slightly lower conductance
(about 300 pS) [73]. Furthermore, yeast strains lacking the e and/or g
subunits,which are necessary for dimer formation, showed a remarkable
resistance to PTP opening [73]. Although strains lacking subunits e [74]
or g [75] display abnormal morphology, with balloon-shaped cristae
and F-ATP synthase monomers distributed randomly in the membrane,
they did develop a normal membrane potential [73], suggesting that
the increased resistance to PTP opening may not depend on these struc-
tural differences. Based on these ﬁndings, it has been proposed that the
PTP forms from F-ATP synthase dimers, possibly in the lipid region
between two adjacent stalks [76].
The idea that the pore forms from the F-ATP synthase is also
supported by two independent studies. Bonora et al. used targeted inac-
tivation of the c subunit of F-ATP synthase – which forms the H+-
transporting c ring of F-ATP synthases – to show that HeLa cells become
resistant to PTP opening and cell death [77]; while Alavian et al.
reconstituted the c subunit or the puriﬁed F-ATP synthase in liposomes,
and measured Ca2+-activated channels [78] with properties similar to
those described by Giorgio et al. with puriﬁed dimers [72]. It is not pos-
sible to derivemechanistic insights about the nature of the PTP-forming
channel from the study of Bonora et al. because the consequences of
knockdown of the c subunit on other components of the F-ATP synthase
and on other mitochondrial proteins were not addressed, and it is
unclear whether and how many functional F-ATP synthases were left
after the knockdown of the c subunit [77]. Alavian et al., on the other
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after Ca2+-dependent extrusion of F1, i.e. of theγ subunit [78].We think
that this hypothesis is extremely unlikely for the following reasons:
• Displacement of F1 from FO requires very drastic conditions, such as
treatment with 2 M urea [79] yet a functional FOF1 complex can
be easily reconstituted after treatment with urea, indicating that the
γ/δ/ε subunit reinserts into FO. It is hard to envision a plausible mech-
anism through whichmatrix Ca2+ could cause release of F1, and then
create within FO a channel that cannot be closed by subunit γ/δ/ε [78].
• Alavian et al. reported that the “FO channel” can instead be closed by
the β subunit, and suggested that this is the mechanism through
which pore closure occurs in situ [78]. There are major problems
with this proposal, because structural studies have established that
subunit β does not interact with the c ring [80]; and it is not obvious
where the free β subunit would come from, given the extreme resis-
tance of the F1 subcomplex to denaturation. This hypothesis is also
difﬁcult to reconcile with the well established fact that PTP–MMC
opening is readily and fully reversible upon chelation of Ca2+ in
mitoplasts [21], intact mitochondria [81] as well as in reconstituted
dimers of F-ATP synthase [72].
• Channel openings were also seen with preparations of the whole
F-ATP synthase, and these could be inhibited by CsA after the addition
of Ca2+ [78]. If the mechanism of pore opening is “expulsion” of F1 by
Ca2+, it is not easy to explain how the current could be inhibited by
CsA. Indeed, it is ﬁrmly established that CsA inhibits the pore by
removing CyPD, which in turn interacts with F1, not FO [71,72].
• F1 has binding sites that can accommodate directly the effects of Ca2+,
Mg2+, adenine nucleotides and Pi; and through CyPD (un)binding
those of H+, CsA and possibly of oxidants [82]. Any model of the
pore must account for all inducers and inhibitors, which appear difﬁ-
cult to ﬁt in the c ring, a multimer of identical c subunits.
• Silencing of the ATP5E gene, which encodes the ε subunit, resulted in
downregulation of the F-ATP synthase complex with accumulation of
subunit c, yet mitochondria were more coupled [83], which is the
opposite of what would be expected if the isolated c ring can form
membrane channels.
• McGeoch and coworkers have performed patch-clamp studies of
highly puriﬁed c subunit (which gave a single silver-stained band
and was validated by sequencing) with very different results, as
currents were inhibited rather than activated by Ca2+ [84–86]. It is
legitimate to wonder whether other F-ATP synthase components
were present in the preparation of Alavian et al. that could explain
this discrepancy.
Given that in our hands the PTP-MMC readily forms from F-ATP
synthase dimers but not monomers [72]; and that inactivation of the
“dimerization” subunits e and g in Saccharomyces cerevisiae increases
resistance of the PTP to Ca2+ [73], we favor the idea that the pore
forms at the interface between two monomers in the dimeric enzyme,
as we will discuss further after covering the regulatory role of CyPD.
4. Modulation by cyclophilin D and cyclosporin A
CyPs are ubiquitous, conserved proteins possessing peptidyl prolyl
cis-trans isomerase activity [87–89]. Sixteen isoforms have been found
in man, and the most abundant (and the ﬁrst to be discovered) is cyto-
solic CyPA [90]. The enzymatic activity of all CyPs is inhibited byCsA [91]
and the CsA/CyPA complex inhibits the cytosolic phosphatase calcine-
urin [92]; as a result, NFAT is no longer dephosphorylated, an event
that prevents its nuclear translocation causing immunosuppression
[93,94].
Mammals possess a unique mitochondrial species called CyPD,
which in the mouse is encoded by the Ppif gene (see [95] for a review).
CyPD is themitochondrial receptor for CsA andmodulates the PTP, but it
is not a structural pore component. Indeed, the PTP can still open inmi-
tochondria from Ppif−/−mice, although higher Ca2+ loads are required[67–70]. Regulation by CyPD may be a relatively recent evolutionary
event [96], since the PTPs of S. cerevisiae and D. melanogaster are insen-
sitive to CsA [97,98]. As also discussed elsewhere, the effect of CsA on
the mammalian PTP is best described as “desensitization” in the sense
that the PTP can still occur but becomes more resistant to Ca2+, Pi and
other inducers [25,76]. This consideration is important because (i) CsA
can desensitize but not block the PTP, and therefore lack of sensitivity
to CsA does not necessarily imply that the PTP is not involved in the
event being studied; and (ii) different cells express different levels of
CyPD, and obviously only CyPD-expressing mitochondria can respond
to CsA [99].
CyPD binds the lateral stalk of F-ATP synthase (OSCP, b and d sub-
units) [71]. Like PTP induction, binding requires Pi (and results in partial
inhibition of ATP synthase activity); while CsA displaces CyPD resulting
in enzyme reactivation [71]. We have recently identiﬁed the binding
site of CyPD to the OSCP subunit, possibly in a region comprising helices
3 and 4 [72], which is also the binding site of Bz-423 [100,101]. In keep-
ing with PTP formation by F-ATP synthase, decreased levels of OSCP
halved the threshold Ca2+ load required for PTP opening [72].
As discussed in detail elsewhere [72,76] we assume that the PTP
forms within the IMM at the interface between two adjacent FO sectors.
Matrix Ca2+ would have an essential permissive role in PTP formation
after binding to the catalytic Me2+-binding site, which is usually occu-
pied byMg2+, and could be inﬂuenced by OSCP. Our working hypothe-
sis is that OSCP as such is a “negative” modulator, whose effect can be
counteracted by binding of the “positive” effector CyPD (which indeed
decreases the threshold Ca2+ required for PTP opening). Removal of
OSCP, or CyPD binding to OSCP, would induce similar conformational
effects on the rigid stalk proteins, leading to increased probability of PTP
opening at the IMM — a working hypothesis that awaits experimental
testing.
We note that PTP formation at themembrane interface between two
stalks could also accommodate the PTP-modulating effects of fatty acids
[5–7,102]. The role of cardiolipin should also be explored, as it stabilizes
respiratory supercomplexes [103] and, due to its partitioning into high-
curvature membrane regions, plays a role in cristae formation and
morphology [104]. Indeed, cardiolipin increases the degree of oligomer-
ization of F-ATP synthase by promoting the formation of extended
dimer rows, which is compromised in D. melanogastermutants defec-
tive for cardiolipin synthesis [104]. The high susceptibility of cardiolipin
to oxidation might alter F-ATP synthase conformation, affecting in turn
the PTP open probability.
5. Regulation of the permeability transition by the outer
mitochondrial membrane
The PT is an innermembrane event, since it also occurs inmitoplasts,
i.e. mitochondria stripped of the OMM [105], yet the OMM does play a
role in pore modulation. Lê-Quôc and Lê-Quôc were the ﬁrst to show
that induction of the PTP by substituted maleimides requires the OMM
[106]. We have conﬁrmed that PTP opening by N-ethylmaleimide is no
longer present in mitoplasts [63] and extended the “sensitizing” role
of the OMM to protocols where the PTP is modulated by dicarboxylic
porphyrins plus visible light, a treatment that leads to the efﬁcient pro-
duction of singlet oxygen [107]. Low light doses inactivate the PTP
through degradation of hystidyl residues, which in turn preventsmatrix
cysteine oxidation [108], possibly through a conformational change;
while higher light doses activate the PTP through OMM cysteine oxida-
tion [109]. PTP activation strictly required an intact OMM, since the
inducing effect of hematoporphyrin plus light was completely lost in
mitoplasts [105]. Largely based on the effect of its ligands on the PTP,
it was proposed that the OMMprotein responsible for PTP sensitization
was the peripheral benzodiazepine receptor (today called TSPO) [52,53,
105,110–112], but this turned out to be incorrect.
It had been known for some time that many cellular effects of “TSPO
ligands” were not due to an interaction with TSPO, suggesting the
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PTP modulation, however, was identiﬁed only recently by 2 indepen-
dent sets of observations. The Glick laboratory discovered that “TSPO li-
gands” (including the benzodiazepine Bz-423 and PK11195) interact
with the mitochondrial F-ATP synthase and affect its activity [100,101,
115,116]; while Giorgio et al. demonstrated that Bz-423 mimics
the PTP-inducing effects of CyPD, and is able to favor the Ca2+- and
oxidant-induced transition of F-ATP synthase dimers to unselective
high-conductance channels [72]. Thus, TSPO ligands directly modulate
the propensity of F-ATP synthase to form channels; and itmay therefore
come as no surprise that mitochondria frommice with genetic ablation
of TSPO (which completely lack high-afﬁnity binding sites for PK11195)
respond with PTP induction to PK11195, N-ethylmaleimide and
photooxidative stress [63]. Thus, TSPO is not responsible for the PTP-
modulating effects of “TSPO ligands”, and the protein(s) responsible
for pore induction by N-ethylmaleimide and photooxidative stress
await clariﬁcation. A potential candidate is Abcb6, an ATP binding
cassette transporter of the OMM involved in heme and porphyrin
homeostasis [117].
It is worth mentioning that the vast majority of F-ATP synthase
dimers is located in rows of oligomers inside cristae [75,118,119]
where a direct interaction with the OMM is not possible. Thus, either
the PTP forms in the small population of dimers facing the intermem-
brane space, where direct contactwith the OMMcan occur; or the effect
of the OMM is exerted by controlling the diffusion of PTP-regulating
metabolites and ions, including Ca2+ itself [120,121] in a process that
would be greatly favored by, and contribute to, cristae remodeling
[122].
The OMM may also affect the outcome of PTP opening without
directly affecting its open-closed transitions. Indeed, it has been shown
that the PT causes matrix swelling and OMM rupture only in the pres-
ence of Bax and Bak, whose genetic ablation confers OMM resistance to
swelling, thus preventing organelle rupture and cell death [123].
6. Cyclosporin A and cardioprotection
Treatment with CsA confers remarkable protection against acute
myocardial injury induced by post-ischemic reperfusion [37], and
this is matched by genetic ablation of CyPD [67,69], which suggests
that the protective effects of CsA depend on CyPD inhibition and, by
inference, on PTP desensitization.
Cardioprotection by CsA has been described in a wide variety of
experimental models and animal species including humans [124]. All
in all, we think that CsA provided a terriﬁc proof of concept about the
causative role of the PTP in I/R injury of the heart, and as a target for
cardioprotection. There may be exceptions, however, as lack of protec-
tion by CsA has been reported in in vivo I/R in rat [125] and pig hearts
[126], while a recent report has instead conﬁrmed the cardioprotective
efﬁcacy in pig hearts [127]. The basis for these discrepancies is not im-
mediately obvious, but key elements could be the duration of ischemia,
which determines severity of damage [128], and CsA dosage [37]. In an
apparent paradox, in perfused hearts of Ppif−/− (CyPD null) mice the
extent of necrosis increased when reperfusion was established after a
relatively short ischemic episode (30 min), while the expected protec-
tionwas observedwhen ischemiawas prolonged to 60min [128]. Addi-
tional studies should address the factors involved in mild I/R damage
that are not affected by treatments targeting CyPD.
Regarding dosage, it should be recalled that the protective effect of
CsA is observed in a very narrow dosage window; this was ﬁrst shown
in perfused rat hearts where protection was seen at 0.2 but not 1 μM
[37], aﬁnding that has been conﬁrmedby several laboratories, including
ours, and never disputed. It seems possible that the effective CsA con-
centration may differ in different species, and therefore that conditions
deﬁned as optimal in one model may prove ineffective in others.
The limitations discussed above, however, must be seriously taken
into account when devising possible clinical applications for CsA, alsoconsidering the potentially adverse effects of prolonged PTP inhibition
in failing hearts [129].
7. Additional effects of cyclophilin D and cyclosporin A
In the mouse CyPD is encoded by a unique nuclear gene (Ppif), and
the transcript includes a matrix targeting sequence that is removed
from the protein after mitochondrial import [130]. Consistently, the
protein localizes to the mitochondrial matrix as detected both by elec-
tron microscopy and by trypsin titrations of mitochondrial fractions
[131,132]. Protection afforded by deletion of CyPD or its inhibition is
generally referred to its localization in the mitochondrial matrix,
which allows regulatory interactions with F-ATP synthase and the PTP.
CyPD has been proposed as a key interactor for the Hsp90–Trap-1
complex [133] and for p53 [134]. By sequestering a relevant fraction
of CyPD these proteins would reduce the probability of PTP opening
thus favoring survival of cancer cells, a provocative hypothesis that is
the subject of controversy [135].
Genetic ablation of CyPD also causedmild ER stress, as judged on the
basis of increased phosphorylation of eIF2a and expression of GRP78
without changes of the potentially detrimental CHOP [136]. This mild
ER stress appears necessary to protect the heart against I/R injury by
preventing the severe ER stress associated with ischemia and reperfu-
sion. This concept is supported by the observation that inhibition of
ER stress by tauroursodeoxycholic acid abrogated cardioprotection
resulting from CyPD ablation or inhibition, while a moderate ER stress
induced by tunicamycin reduced post-ischemic reperfusion injury
[136]. More recent work from the Ovize laboratory suggests that CyPD
contributes to Ca2+ trafﬁcking between ER/SR and mitochondria by
binding to a protein complex which also includes VDAC1, Grp75 and
IP3R1 [137]. This complex appears to be located at the interface
between theOMMand theER, andmay facilitate the transfer of Ca2+ re-
leased from the ER into the mitochondrial matrix [138]. Interestingly,
the CyPD–VDCA1–Grp75–IP3R1 interactionwas facilitated bymitofusin
2, and increased under conditions of hypoxia and reoxygenation [137].
This complex may be extremely relevant because the genetic ablation
or the pharmacological inhibition of any of its members decreased the
occurrence of cell death induced by protocols of anoxia/reoxygenation
or ischemia/reperfusion [137].
Whether this additional role for CyPD is relevant to PTP regulation in
relation to Ca2+ is an open question. PTP opening does not depend on
VDAC [61,62], and mitochondrial Ca2+ uptake occurs through MCU in
aΔψm-dependent process [139,140]. PTP opening curtails mitochondri-
al Ca2+ uptake both by disrupting Δψm and by providing a possible
pathway for Ca2+ efﬂux [32–35], consistent with the ﬁnding that
CyPD ablation or inhibition leads to an increase of matrix [Ca2+] [34,
129,141].
An obvious question is whether can CyPD also be found outside the
matrix and in the ER/SR. This question applies both to CyPD interactions
with the VDAC1–Grp75–IP3R1 complex, and to those with other
proteins shown to bind CyPD mostly by immunoprecipitation such as
Bcl-2 [142], p53 [134,135], GSK-3 [131] and the Hsp90–Trap-1 complex
[133]. These ﬁndings would imply that a fraction of CyPD is localized at
sites other than the mitochondrial matrix, or that under speciﬁc patho-
physiological conditions CyPD translocates to other cellular sites. Until
such mechanism is identiﬁed, chances remain that results obtained
with detergent extraction and immunoprecipitation may not reﬂect
the protein–protein interactions involving CyPD in situ.
It should also be mentioned that the effects of CyPD on proteins lo-
cated outside mitochondria need not be only due to direct protein–
protein interactions, but might also be related to functional modiﬁca-
tions induced by CyPD deletion or inhibition, as well as by covalent
changes in response to the activation of signaling pathways [143].
These include (de)phosphorylation [131], (de)acetylation [144],
nitrosylation [82,145] and oxidation of Cys203, which inhibits the enzy-
matic activity of CyPD and plays a crucial role in favoring PTP opening.
104 P. Bernardi, F. Di Lisa / Journal of Molecular and Cellular Cardiology 78 (2015) 100–106Importantly, expression of a CyPDC203S mutant desensitized the PTP to
both Ca2+- and H2O2 providing a mechanistic link between oxidative
stress and PTP opening [82]. This wide array of CyPD modiﬁcations,
which has largely been characterized in E. Murphy's laboratory, is likely
to affectmitochondrial metabolism, eventually resulting in variations of
responses to physiological and pathological stimuli. In keepingwith this
possibility ablation of CyPD causes signiﬁcant changes in the level of
mitochondrial proteins involved in intermediary metabolism [146] as
well as in the mitochondrial acetylome [147]. Interestingly, increased
acetylation of β-hydroxyacyl-CoA dehydrogenase resulted in a 50%
decrease of its activity [147], which may explain the decreased fatty
acid oxidation observed in Ppif−/− hearts [129].
CsA inhibits all CyP isoforms, and this can be an important confounder
in evaluating its mitochondrial effects. Indeed, inhibition of calcineurin,
which is mediated by the complex of CsA with cytosolic CyPA [92,93],
prevents dephosphorylation of the pro-ﬁssion protein Drp-1 at Ser637,
thus hampering itsmitochondrial translocation and therefore fragmenta-
tion, a cytoprotective mitochondrial effect of CsA that is not related to
PTP inhibition [148,149]. Of note, genetic ablation or pharmacological
inhibition of Drp1 has been shown to afford signiﬁcant protection
against cardiomyocyte injury caused by ceramide, hyperglycemia and
post-ischemic reperfusion [150–152].
This effect of CsAmay be counteracted by other processes in the con-
text of myocardial ischemia. Thus, lack of Ser637 dephosphorylation due
to calcineurin inhibition can be contrasted by the activating effect of
Ser616 phosphorylation [153], a process catalyzed by various protein
kinases including PKCδ that is generally considered detrimental for the
survival of ischemic cardiomyocytes [153]. The protective effect of CsA
could be further limited by direct stimulation of HIF-1α Pro564 hydrox-
ylation, which leads to increased removal of HIF-1α and may thus
prevent adaptation to hypoxia, an effect originally described in glioma
cells [154] that should now be investigated in cardiomyocytes.
8. Summary and perspectives
The discovery that the PTP forms from the F-ATP synthase is
redirecting research toward the mechanisms that switch this key
enzyme from an energy-conserving to an energy-dissipating device.
These hold great promise to improve our understanding of the patho-
physiological events that trigger the transition in heart diseases, and
to set a logical frame for therapeutic strategies. CyPD remains a viable
target, and we are conﬁdent that the current hurdles between preclini-
cal studies and clinical application of PTP-inhibitory strategies will be
overcome by more speciﬁc inhibitors of CyP isoforms [155], by drugs
targeting the PTP at sites other than CyPD [156] and by their combina-
torial use.
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